This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.
biotechnology biotechs earnings medical
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
by Zacks Equity Research
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
GILDNegative Net Change INCYPositive Net Change SRPTNegative Net Change VTVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
by Zacks Equity Research
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
REGNPositive Net Change SNYPositive Net Change NVSPositive Net Change PFENegative Net Change
biotechs medical pharmaceuticals
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
RHHBYPositive Net Change DVAXNegative Net Change GILDNegative Net Change PBYIPositive Net Change
biotechs
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?
by Kinjel Shah
We suggest that investors who own GSK's stock remain invested for now, considering its sales and profits are expected to continue improving in the coming years.
GSKPositive Net Change NVOPositive Net Change LLYPositive Net Change HLNPositive Net Change
biotechs
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
DVAXNegative Net Change GILDNegative Net Change ARVNNegative Net Change IMVTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
NVSPositive Net Change RHHBYPositive Net Change DVAXNegative Net Change GILDNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
by Zacks Equity Research
Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'
RHHBYPositive Net Change SRPTNegative Net Change ANIPPositive Net Change CTMXNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
JAZZNegative Net Change AXSMNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
by Zacks Equity Research
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
RDYNegative Net Change AMGNPositive Net Change GILDNegative Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, it is yet to record product sales.
VRTXNegative Net Change BEAMPositive Net Change NTLANegative Net Change CRSPPositive Net Change
biotechs crispr gene-therapy medical
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
GSKPositive Net Change BMRNNegative Net Change GILDNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
GSKPositive Net Change PFENegative Net Change MRKPositive Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
RHHBYPositive Net Change MRKPositive Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs cancer medical oncology-screening pharmaceuticals
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
by Ekta Bagri
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
by Zacks Equity Research
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
AMGNPositive Net Change ANIPPositive Net Change CTMXNegative Net Change
biotechs medical pharmaceuticals
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
VRTXNegative Net Change MRNANegative Net Change CRSPPositive Net Change
biotechs
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
by Zacks Equity Research
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
AZNPositive Net Change BMRNNegative Net Change GILDNegative Net Change CORTNegative Net Change
biotechnology biotechs cell-therapy immuno-therapy medical oncology-screening pharmaceuticals
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
by Zacks Equity Research
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
JAZZNegative Net Change ACADNegative Net Change AXSMNegative Net Change
biotechs
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
by Zacks Equity Research
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
BIIBNegative Net Change LLYPositive Net Change
biotechs
Will ADMA Biologics Stock Continue Its Momentum in 2025?
by Zacks Equity Research
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
by Zacks Equity Research
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
ANIPPositive Net Change CTMXNegative Net Change ALLOPositive Net Change ETNBNegative Net Change
biotechs cell-therapy earnings medical
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
by Zacks Equity Research
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMRN's Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan
by Zacks Equity Research
Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.
DVAXNegative Net Change BMRNNegative Net Change AMRNPositive Net Change ARVNNegative Net Change
biotechs earnings
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILDNegative Net Change JAZZNegative Net Change
biotechnology biotechs cancer cell-therapy earnings immuno-therapy investing medical oncology-screening pharmaceuticals